Pfizer Inc. vaccine is around 91% effective in preventing respiratory disease, they said on Thursday, citing updated trial data that included participants inoculated for up to six months. The shot was 100% effective in preventing illness among trial participants in South Africa, where a new variant called B1351 was dominant, although the number of participants was relatively small at 800.
While the overall efficacy rate was only 91.3% lower than 95%, which was initially reported in November for a trial of 44,000 people, several variants became more common worldwide since then. The Head of the Executive Pfizer, Albert Bourla, said the updated results, which included more than 12,000 people, were fully inoculated for at least six months, positioning drug makers to send full US regulatory approval.
- Pfizer Covid vaccine 95% effective and safe, final analysis shows
- Israel Election: Netanyahu Hopes For Another Term Amid Vaccine Rollout
This vaccine is currently authorized for emergency use by Food and Drug Administration. Experimental data “provides the first clinical results that vaccines can effectively do on the current circulation variant, an important factor to achieve herd immunity and end this pandemic for the global population,” said Chief Executive Bionech Ogur Sahin in a statement.
Experts worry that Covid-19 new variants from South Africa and Brazil can be resistant to existing vaccines and treatments. More than 300 cases of South Africa variants have been detected in more than 25 countries and jurisdictions, federal data shows.
This vaccine is 100% effective in preventing severe diseases as defined by the American CDC and 95.3% effective in preventing extreme conditions as determined by Food and Drug Administration. Also, there were no serious security problems observed in trial participants for up to six months after the second dose, the company said.
They added that it was generally equally effective regardless of age, race, gender, or ethnicity and among participants with various medical conditions. “This data strengthens our view that we have some powerful vaccines,” said Danny Altmann, a professor of immunology in the London Imperial College of England, who was not involved in the Pfizer trial.
He said the South African variant’s effectiveness was “especially worth noting” because it showed this vaccine the possibility of offering adequate protection in real-world settings where several different Coronavirus variants could circulate. The trial reviewed more than 900 confirmed Covid-19 cases, mostly among participants who received a placebo.
The release of updated results came on separate data heels that showed a safe and effective vaccine at the age of 12 to 15 years, paving the way for drugmakers to seek the US and European approval to use shots in this age group in the week.
Have a tip we should know? email@example.com